All r/r MM patients had previously been treated with Len, Bort, and DXM, and a median of three prior lines of treatment (range 2–7), including autologous stem cell transplantation, daratumumab, BCMA-CAR-T, etc. (Table 1, Supplementary Table 3). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.